Generation Bio Co (GBIO) Return on Equity ROE from the third quarter 2025 to third quarter 2024 and annually, average high and low, overall ranking from Sep 30 2025 to Sep 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Generation Bio Co   (NASDAQ: GBIO)

Generation Bio Co 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Generation Bio Co in the third quarter 2025?
Generation Bio Co recorded a cumulative net loss of $-63 million during 12 months ending in the third quarter 2025, resulting in a negative return on equity (ROE) of -94.82%.

Within the Major Pharmaceutical Preparations industry 252 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2025 from 2746 to 3527.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter
Y / Y Equity Change -51.59 % -53.12 % -44.44 % -57.56 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -63 -72 -72 -132 -145
Return On Equity (TTM) -94.82 % -91.07 % -75.84 % -120.23 % -104.85 %
GBIO's Total Ranking # 3527 # 2746 # 2981 # 2659 # 3331
Equity (TTM) in Millions 51 54 73 86 104
Seq. Equity Change -6.55 % -26.22 % -14.93 % -17.46 % -9.5 %
Seq. Net Income Change - - - - -

Back to GBIO Management Effectiveness >> GBIO's 5 Years Annual ROE >> Compare GBIO ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 253
Sector # 555
Overall # 3527

Return On Equity Statistics
High Average Low
-7.76 %
-55.96 %
-120.23 %
(Mar 31 2021)   (Dec 31 2024)



  News about Generation Bio Co Return on Equity ROE

Augmenting Treatment for T Cell-Driven Autoimmune Diseases Generation Bios Strategic Deployment of ctLNP Techno...

In a groundbreaking move within the biotechnology sector, Generation Bio Co. (Nasdaq: GBIO) is making strides in developing innovative therapeutics for T cell-driven autoimmune diseases. The company recently announced its strategy to utilize its proprietary T cell-directed lipid nanoparticle (ctLNP) technology for the delivery of small interfering RNA (siRNA) therapeutics, poised to silence disease-causing targets within T cells. This approach not only underscores Generation Bio s commitment to therapeutic advancements but also highlights the potential to address previously deemed untreatable medical challenges. Key Facts1. Technology Deployment : Generation Bio is leveraging its validated ctLNP technology to specifically deliver siRNA to T cells. This capability allows for targeted modulation of T cell activity in vivo, with the aim to silence therapeutic targets associated with inflammatory responses and tissue damage prevalent in autoimmune diseases.



GBIO Annual Return On Equity (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Equity in Millions 86 203 282 382 268
Y / Y Equity Change -57.56 % -28.09 % -26 % 42.44 % -
Net Income in Millions -132 -127 -137 -119 -81
Y / Y Net Income Change - - - - -
Return On Equity -152.74 % -62.33 % -48.37 % -31.21 % -30.04 %

Back to GBIO Management Effectiveness >> GBIO's 5 Years Annual ROE >> Compare GBIO ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
GBIO's' Return on Equity at Yahoo Finance
GBIO's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for GBIO's Competitors
Subscribers only: Roe for Generation Bio Co 's Suppliers
Subscribers only: Return On Equity for GBIO's Customers




Companies with similar Return On Equity at Sep 30 2025, within Healthcare Sector ROE

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.